These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10411482)

  • 1. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
    Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
    J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
    Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
    J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,3-Disubstituted benzazepines as neuropeptide Y Y1 receptor antagonists.
    Murakami Y; Hagishita S; Okada T; Kii M; Hashizume H; Yagami T; Fujimoto M
    Bioorg Med Chem; 1999 Aug; 7(8):1703-14. PubMed ID: 10482462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
    Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
    J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
    Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
    Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptide Y as a partial agonist of the Y1 receptor.
    Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL
    Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
    Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
    Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.
    Wieland HA; Engel W; Eberlein W; Rudolf K; Doods HN
    Br J Pharmacol; 1998 Oct; 125(3):549-55. PubMed ID: 9806339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
    Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]-BIBP3226 and [3H]-NPY binding to intact SK-N-MC cells and CHO cells expressing the human Y1 receptor.
    Vanderheyden PM; Van Liefde I; de Backer JP; Vauquelin G
    J Recept Signal Transduct Res; 1998; 18(4-6):363-85. PubMed ID: 9879066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists.
    Zarrinmayeh H; Nunes AM; Ornstein PL; Zimmerman DM; Arnold MB; Schober DA; Gackenheimer SL; Bruns RF; Hipskind PA; Britton TC; Cantrell BE; Gehlert DR
    J Med Chem; 1998 Jul; 41(15):2709-19. PubMed ID: 9667962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of G protein and phospholipase C-coupled agonist binding to the Y1 neuropeptide Y receptor in rat brain: sensitivity to G protein activators and inhibitors and to inhibitors of phospholipase C.
    Parker SL; Parker MS; Sweatman T; Crowley WR
    J Pharmacol Exp Ther; 1998 Jul; 286(1):382-91. PubMed ID: 9655883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 receptor antagonists.
    Dove S; Michel MC; Knieps S; Buschauer A
    Can J Physiol Pharmacol; 2000 Feb; 78(2):108-15. PubMed ID: 10737673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.